Meningococcal meningitis
diseaseOn this page
Summary
Meningococcal meningitis (MONDO:0018059) is a disease and 59 clinical trials. Top therapeutic interventions include sodium chloride, neisseria meningitidis oligosaccharide conjugated to corynebacterium diphtheriae crm197, and rabies vaccine. A subtype of meningococcal infection — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Europe) [Orphanet-validated]
- Phenotypes (HPO): 35
- Clinical trials: 59
Clinical features
Epidemiology
Prevalence records
4 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | Europe | Validated | |
| Annual incidence | 1-9 / 100 000 | 2.3 | France | Validated |
| Annual incidence | 1-9 / 100 000 | 2.7 | New Zealand | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.8 | United States | Validated |
Signs & symptoms
Clinical features (HPO)
35 HPO clinical features (Orphanet curated; top 35 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001945 | Fever | Very frequent (80-99%) |
| HP:0002922 | Increased CSF protein concentration | Very frequent (80-99%) |
| HP:0011972 | Hypoglycorrhachia | Very frequent (80-99%) |
| HP:0012229 | CSF pleocytosis | Very frequent (80-99%) |
| HP:0025258 | Stiff neck | Very frequent (80-99%) |
| HP:0031179 | Nuchal rigidity | Very frequent (80-99%) |
| HP:0000613 | Photophobia | Frequent (30-79%) |
| HP:0000967 | Petechiae | Frequent (30-79%) |
| HP:0000988 | Skin rash | Frequent (30-79%) |
| HP:0002039 | Anorexia | Frequent (30-79%) |
| HP:0002315 | Headache | Frequent (30-79%) |
| HP:0002587 | Projectile vomiting | Frequent (30-79%) |
| HP:0004372 | Reduced consciousness/confusion | Frequent (30-79%) |
| HP:0011227 | Elevated circulating C-reactive protein concentration | Frequent (30-79%) |
| HP:0100806 | Sepsis | Frequent (30-79%) |
| HP:0000083 | Renal insufficiency | Occasional (5-29%) |
| HP:0000236 | Abnormality of the anterior fontanelle | Occasional (5-29%) |
| HP:0000365 | Hearing impairment | Occasional (5-29%) |
| HP:0000737 | Irritability | Occasional (5-29%) |
| HP:0000979 | Purpura | Occasional (5-29%) |
| HP:0001085 | Papilledema | Occasional (5-29%) |
| HP:0001250 | Seizure | Occasional (5-29%) |
| HP:0001254 | Lethargy | Occasional (5-29%) |
| HP:0002329 | Drowsiness | Occasional (5-29%) |
| HP:0002516 | Increased intracranial pressure | Occasional (5-29%) |
| HP:0002615 | Hypotension | Occasional (5-29%) |
| HP:0003401 | Paresthesia | Occasional (5-29%) |
| HP:0032308 | Increased circulating procalcitonin concentration | Occasional (5-29%) |
| HP:0001297 | Stroke | Very rare (<1-4%) |
| HP:0002045 | Hypothermia | Very rare (<1-4%) |
| HP:0002383 | Infectious encephalitis | Very rare (<1-4%) |
| HP:0002643 | Neonatal respiratory distress | Very rare (<1-4%) |
| HP:0006824 | Cranial nerve paralysis | Very rare (<1-4%) |
| HP:0011880 | Acute disseminated intravascular coagulation | Very rare (<1-4%) |
| HP:0031273 | Shock | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | meningococcal meningitis |
| Mondo ID | MONDO:0018059 |
| EFO | EFO:1001040 |
| MeSH | D008585 |
| Orphanet | 33475 |
| DOID | DOID:0080176 |
| ICD-10-CM | A39.0 |
| ICD-11 | 516585689 |
| SNOMED CT | 192644005 |
| UMLS | C0025294 |
| MedGen | 6299 |
| GARD | 0018809 |
| MedDRA | 10027249, 10027276 |
| NORD | 1438 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of meningococcal infection. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › meningococcal infection › meningococcal meningitis
Related subtypes (1): meningococcemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
6 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| NEISSERIA MENINGITIDIS OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 | Approved (phase 4) |
| Neisseria Meningitidis Adhesin A | Approved (phase 4) |
| Neisseria Meningitidis Factor H Binding Protein | Approved (phase 4) |
| Neisseria Meningitidis Neisserial Heparin Binding Antigen | Approved (phase 4) |
| Neisseria Meningitidis Outer Membrane Vesicles | Approved (phase 4) |
| Neisseria Meningitidis Polysaccharide Conjugated To Tetanus Toxoid | Approved (phase 4) |
| Diphtheria Toxoid | Phase 3 (in late-stage trials) |
| Pertussis Vaccine | Phase 3 (in late-stage trials) |
| Tetanus Toxoid | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 59.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 29 |
| PHASE2 | 16 |
| PHASE4 | 4 |
| PHASE2/PHASE3 | 3 |
| PHASE1 | 3 |
| PHASE1/PHASE2 | 2 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01424644 | PHASE4 | COMPLETED | A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents |
| NCT02591290 | PHASE4 | COMPLETED | Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects |
| NCT02633787 | PHASE4 | COMPLETED | Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier |
| NCT02864927 | PHASE4 | COMPLETED | Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea |
| NCT06131554 | PHASE3 | ACTIVE_NOT_RECRUITING | A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years |
| NCT06226714 | PHASE3 | ACTIVE_NOT_RECRUITING | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds |
| NCT06700148 | PHASE3 | ACTIVE_NOT_RECRUITING | A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds |
| NCT00329901 | PHASE3 | COMPLETED | Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years |
| NCT00384397 | PHASE3 | COMPLETED | A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers |
| NCT00422292 | PHASE3 | COMPLETED | Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers |
| NCT00450437 | PHASE3 | COMPLETED | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults |
| NCT00474487 | PHASE3 | COMPLETED | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults |
| NCT00483574 | PHASE3 | COMPLETED | Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers |
| NCT00518180 | PHASE3 | COMPLETED | A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents |
| NCT00667602 | PHASE3 | COMPLETED | Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers |
| NCT00856297 | PHASE3 | COMPLETED | Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine |
| NCT00944034 | PHASE2/PHASE3 | COMPLETED | Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 |
| NCT01148017 | PHASE3 | COMPLETED | Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine |
| NCT01148524 | PHASE2/PHASE3 | COMPLETED | Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 |
| NCT01192997 | PHASE2/PHASE3 | COMPLETED | Comparison of Two Meningococcal ACWY Conjugate Vaccines |
| NCT01214837 | PHASE3 | COMPLETED | Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life |
| NCT01274897 | PHASE3 | COMPLETED | A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea |
| NCT01339923 | PHASE3 | COMPLETED | A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years |
| NCT01423084 | PHASE3 | COMPLETED | Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years |
| NCT01453348 | PHASE3 | COMPLETED | Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine |
| NCT01466387 | PHASE3 | COMPLETED | A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults |
| NCT01478347 | PHASE3 | COMPLETED | A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults |
| NCT01519713 | PHASE3 | COMPLETED | Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects |
| NCT01717638 | PHASE3 | COMPLETED | Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 |
| NCT01894919 | PHASE3 | COMPLETED | Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 |
| NCT02752906 | PHASE3 | COMPLETED | Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine |
| NCT02842853 | PHASE3 | COMPLETED | Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine |
| NCT02842866 | PHASE3 | COMPLETED | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older |
| NCT02955797 | PHASE3 | COMPLETED | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers |
| NCT03077438 | PHASE3 | COMPLETED | Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years |
| NCT03964012 | PHASE3 | COMPLETED | Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) |
| NCT00310817 | PHASE2 | COMPLETED | Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months. |
| NCT00310856 | PHASE2 | COMPLETED | Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months) |
| NCT00355121 | PHASE2 | COMPLETED | Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL® |
| NCT00874549 | PHASE1/PHASE2 | COMPLETED | Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years |